Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer

By sjmartinez • December 20, 2023

Wang R, Mi Y, Ni J, Wang Y, Ding L, Ran X, Sun Q, Tan SY, Koeffler HP, Feng N, Chen YQ. Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2023 Dec 20:e2304939. doi: 10.1002/advs.202304939. Epub ahead of print. PMID: 38115765.

Tags: castration-resistant prostate cancer, Cedars Sinai DoM, Drug-tolerant persister, Hematology/Oncology, peroxiredoxin 5, polaprezinc, Publications, stachyose

Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous ECG Monitoring Follow-Up: ADVANTAGE AF-Phase 2

Reddy VY, Gerstenfeld EP, Schmidt B, Andrade JG, Nair D, Natale A, Saliba W, Sommer P, Metzner A, Verma A, Hounshell T, Amin A, Gentlesk[...]

Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)

Aggarwal R, Pongtarakulpanit N, Sullivan DI, Moghadam-Kia S, Bae SS, Wilkerson J, Saygin D, Marder G, Venuturupalli S, Dellaripa PF, Danoff SK, Doyle T, Hunninghake[...]

Development and Validation of Crohn’s Perianal Fistula Educational Videos and Website for Increasing Patient Knowledge and Engagement

Khalil C, Mehra M, Yang Y, Choi SY, Ballesteros J, Krut Z, Bonthala N, Zaghiyan K, Gu P, Yeo YH, Spiegel BMR, Almario CV. Development[...]